



SDI Review Form 1.6

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	Ms_IJBCRR_24832
Title of the Manuscript:	EARLY DETECTION OF PROSTATE CANCER: IMMUNOASSAY FOR SERUM PROSTATE SPECIFIC ANTIGEN (PSA) TUMOR MARKER.
Type of the Article	Review paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The manuscript entitled "Early Detection Of Prostate Cancer: Immunoassay For Serum Prostate Specific Antigen (PSA) Tumor Marker" has relevance because relate features of an important tumor that affects the men. As a review, the manuscript present several problems: 1. The authors should better describe the importance of the patient age as a risk factor to this cancer development. 2. The references are poor. Among 40 the references, only 4 were published after 2000. In my opinion the text needs improvement and news references must be included.	The biopsy rate has been shown to decrease approximately 21% in older men undergoing screening if age-specific reference ranges remains controversial: some investigators have shown no benefit to their use as compared to use of the standard cut off point of 4.0ng/ml. There are contradictory guidelines by medical organizations on screening for prostate cancer. The recommendation for prostate cancer screening by the American Urological Association and the American Cancer Society is for all men aged 50years and above with life expectancy >10years and starting at age 40-45years for high-risked men (e.g. African Americans and those with affected first degree relatives) [41, 42] However the national Cancer Institute [43] and the United States Preventive Service Task Force [44] do not recommend screening for prostate cancer in the general population or high risk individuals. Prostate cancer screening may reduce mortality from the disease almost by half but with a substantial risk of over diagnosis [45]. The European Randomized Study of Screening for Prostate Cancer



SDI Review Form 1.6

		(ERSPC) also demonstrated that population-based screening of men aged 55-75 years can reduce prostate cancer mortality [46, 47]. ADDITIONAL REFERENCES 1. AUA American new guideline on prostate cancer screening. April 2009 http://www.auanet.org/education/guideline/prostate cancer detection cfm. Accessed December 2012 2. Smith RA, Cokkinides V, Egre HJ. American cancer society guidelines for the early detection of cancer 2003. CA cancer J. Clin 2003 Jan- Feb: 53 (1): 27-43 Pub Med /Google Scholar. 3. National Cancer Institute prostate cancer screening http://www.cancergor/cancertopics/pdq/screening/prostate/patient . Accessed December 2012 4. US preventive Services Task force Updates prostate cancer screening recommendations 2008 http://www.acponline.Org/pressroom/pcancer.htm Accessed December 2012 5. Huggosson J, Carlssons, Ans G Mortality results from the Goteborg randomized population-based prostate cancer screening trial. Lancet oncol. Aug, 2010. 11 (8): 725-32. Pub Med/Google scholar. 6. Schroder FH, Huggosson J, Roobed MJ, Prostate Cancer mortality in randomized European study. N. Eng/J med Mar
--	--	--



SDI Review Form 1.6

		2009, 26 (12): 360: 320-8 pub med /Google scholar. 7. Scholar FH, Hugosson J. Roobol MJ. Prostate cancer mortality at 11 years of follow-up. N. Eng/J. med mar 2012; 15: 366 (11): 981-90. Pub Med/Google scholar. 8. Ogunbuyi JO, Shittu OB. Increased in advance of prostate cancer in Nigeria. J Natt Med Assoc. Mar, 1999; 9 (3): 159-64. Pub med /Google scholar 9. Mohammed AZ, Edino ST, Odirdia O, Guarzo AK, samaila AA, Cancer in Nigeria : a 10-year analysis of the Kano cancer registry. Niger J.med Jul-Aug, 2008; 17 (3): 280-4. Pub med/Google scholar. 10. Osegba DN, Prostate cancer in Nigeria facts and nonfacts J. Urol April 1997: 157 (4) : 1340-3 Pub.med/Google scholar 11. Badmus TA, Adesumkanmi, AR, Yusuf BM. Burden of Prostate cancer in southwestern Nigeria Urology. Aug 2010: 76 (2) : 412-6 Pubmed /Google scholar 12. Fradet Y, Klotz L, Trachtenbery J, Zlotta A. the burden of prostate cancer in Canada. Can Urol Assoc J Jun 2009: 3(suppl 2) s92-s100. Pub med/Google Scholar. 13. Odediran FT, Ogunbiyi Jo Ukolo FA. Roots of Prostate cancer in African-American men. J Natt med Assoc April
--	--	---



SDI Review Form 1.6

		2006; 98 (4):539-43 Pub med/Google scholar. 14. Odedina FT, Akinremi TO, Chunegwuandoh F. Prostate cancer disparities in Black Man of African descent: A comparative literature review of prostate cancer burden among Black men in the United states , caribbean United kingdom , and west Africa infact agent cancer 2009; 4 (suppl 1).52 pub med /Google scholar 15. Agape AA, Babata A, Abiola oo, Knowledge of prostate cancer screening among nature African Urban population in Nigeria .MYQJ Hospital Med April-Jan 2010;20(2)94-6. Pub Med/ Google scholar 16. Ukoli F, Osime U, Akinyemi,F, Okunzuwa O, K.H.les R Adama-Campbell L. Prevalence of elevated serum prostate specific antigen in rural Nigeria . Int J urol jun2003; 10 (6) :315-22 pub med/Google scholar 17. Rabah DM, Araga MA, prostate cancer screening in a Sandi population an exemplary trial study. Prostate cancer prostatic Dis. Jun 2010: 13 (2): 191-4 Pub Med/Google scholar 18. Ross LE, Coates RJ, Breen N, Ujler RJ. Potosky AL, Black man D. prostate-specific antigen test use reported in the 2000 National Health Interview survey. Prev Med .Jun 2004: 38 (60: &32-44 Pub Med/Google scholars.
--	--	--



SDI Review Form 1.6

		19. Abbiyesuku FM, Shittu OB, Oduwole oo, Osatimelum BO, Prostate specific antigen in the Nigeria Africa . Afr. J. Med/Google scholar 20. Iknenowo so, Omisanjo OK, poioku MJ, Ajala MD, Nonye Mordi, VP, Esho Jo. Prevalence and Charaateristics of prostate cancer among participants of a community based screening in Nigeria using serum prostate specific antigen and digital rectal examination. The pan African Medical Journal 2013, 15: 129. 2489 Pub Med/Google scholar
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		